Clinical Trial Update: An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine [Phase 2]

View source ↗

Summary

An open-label, randomized Phase II study evaluating Indisulam in combination with capecitabine for metastatic breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Indisulam (indisulam)

Snippet

Sponsor: Eisai Limited | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED